by Solural Pharma | Nov 16, 2022 | News
Solural Pharma has entered an agreement with Contera Pharma A/S to transfer all proprietary rights for the SOL 707 Morning Akinesia to Contera Pharma.
by Solural Pharma | Feb 13, 2018 | News
Solural Pharma ApS receives an updated Manufacturing and Importation Authorisation No. 30108 by the Danish Health and Medicines Authority expanding its manufacturing capabilities from oral products to also include topical products and primary and secondary packaging...
by Solural Pharma | Aug 9, 2017 | News
The European Patent office has announced a decision to grant Solural Pharma a European patent “Solid Oral Dosage Form of Testosterone Derivative.”
by Solural Pharma | Jun 30, 2017 | News
Ascelia Pharma AB acquires Oncoral Pharma ApS and its novel tablet based proprietary formulation of the chemotherapeutic agent, irinotecan, which today is only available as an intravenous infusion product. Solural Pharma will continue to support Ascelia Pharma with...
by Solural Pharma | Jun 20, 2017 | News
The United States Patent and Trademark office has issued the Solural patent “Solid Oral Dosage Form of Testosterone Derivative”.
